The phase 1 trial results were presented in greater detail in two posters at ASCO 2017 in Chicago this week.
Professor Phil Clingan presented a poster: Deflexifol (a novel formulation of 5FU) Phase 1 Dose Escalation Study of Infusional or Bolus Schedules After Failure of Standard Treatment
Clingan P. et al J Clin Oncol 35, 2017 (suppl; abstr 2529) http://abstracts.asco.org/199/AbstView_199_188458.html
Professor Stephen Ackland presented another poster about the trial: Deflexifol (a novel formulation of 5FU): Pharmacokinetics in a Phase 1 Trial in Comparison to 5FU
Ackland S. et al J Clin Oncol 35, 2017 (suppl; abstr 2530) http://abstracts.asco.org/199/AbstView_199_189228.html.